Related Experiment Video
Updated: Apr 29, 2026

Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
The effect of PPI use on human gut microbiota and weight loss in patients undergoing laparoscopic Roux-en-Y gastric
Emily K Ward1, Dara P Schuster, Katie H Stowers
1Division of Gastroenterology and Hepatology, University of Colorado Denver, Academic Office Building 1, 12631 East 17th Avenue, Room 7614, MS B158, Aurora, CO, 80045, USA.
Abstract:
Laparoscopic Roux-en-Y gastric bypass (LRYGB) achieves sustainable weight loss possibly by altering the gut microbiota. The effect of a proton pump inhibitor (PPI) on weight loss and the gut microbiota has not been explored. PPI use and the gut microbiota were assessed before and 6 months after LRYGB in eight patients. Bacterial profiles were generated by 16S ribosomal RNA (rRNA) gene sequencing. Prior to LRYGB, PPI users had a higher percent relative abundance (PRA) of Firmicutes compared to nonusers. PPI users at 6 months post-LRYGB had a higher PRA of Firmicutes [48.6 versus 35.6%, p = nonsignificant (NS)] and a trend toward significantly lower percent excess weight loss (49.3 versus 61.4%, p = 0.067) compared to nonusers. PPI use post-LRYGB may impair weight loss by modifying gut microbiota.
Related Concept Videos
Probiotics
Microbiota of the Stomach and Small Intestine
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Treatment of Constipation-Predominant IBS

